Abstract Number: 1420 • ACR Convergence 2022
Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
Background/Purpose: Biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) often are used as monotherapy in rheumatoid arthritis (RA). However, little is known about the comparative effectiveness of…Abstract Number: 1585 • ACR Convergence 2022
Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)
Background/Purpose: Rheumatoid arthritis (RA) patients with inadequate response to methotrexate often experience trial-and-error treatment selection due to a lack of guidance from clinical guidelines or…Abstract Number: 1646 • ACR Convergence 2022
Major Adverse Cardiovascular Events and Mortality with Opioids versus NSAIDs Initiation in Patients with Rheumatoid Arthritis
Background/Purpose: Pain management is challenging in RA where ~60% of patients with well-controlled disease activity still experience bothersome pain. The opioid epidemic in the US…Abstract Number: 1742 • ACR Convergence 2022
Shared Epitope Allomorphs Directly Influence Antigen-specific T-cell Responses in RA
Background/Purpose: The products of rheumatoid arthritis (RA)-associated MHC class II risk alleles HLA-DRB1*04:01 and *04:04 (DR4) differ only by two amino acids in the peptide…Abstract Number: 1785 • ACR Convergence 2022
PROs and Sociodemographic Factors in Year Prior to COVID Predict Trajectories of Depressive Symptoms in Adults with RA in First 2 Years of Pandemic: Data from the Canadian Early Arthritis Cohort
Background/Purpose: Growing evidence points to considerable mental health impacts of the prolonged COVID-19 pandemic, though data from longitudinal studies in rheumatic diseases are sparse. We…Abstract Number: 1962 • ACR Convergence 2022
Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Background/Purpose: Previous studies have demonstrated clinical, epidemiologic, histopathologic, and genetic overlap between advanced rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and Idiopathic Pulmonary Fibrosis (IPF). Corresponding…Abstract Number: 1980 • ACR Convergence 2022
Seroconversion After a Third COVID-19 Vaccination in Rheumatoid Arthritis Patients Treated with (ultra-)low Dose Rituximab with a Previous Insufficient Humoral Response Is Associated with Rituximab Dosage
Background/Purpose: Around 60% of rheumatoid arthritis (RA) patients treated with ≥1000 mg rituximab (RTX) has an insufficient deemed humoral response after two COVID-19 vaccinations. Recent…Abstract Number: 1997 • ACR Convergence 2022
Effects of Short Chain Fatty Acid Supplementation in Modulation of Gut Microbiome and T-Regulatory Cells in Health and New Onset Rheumatoid Arthritis
Background/Purpose: The gut microbiome and its metabolites are dysregulated in rheumatoid arthritis. Short chain fatty acids (SCFAs), microbial fermentation byproducts of certain gut microbes, induce…Abstract Number: 2013 • ACR Convergence 2022
Drug Free Remission in Rheumatoid Arthritis: Data from the Randomized Controlled ARCTIC REWIND Trial
Background/Purpose: Sustained remission has become an achievable treatment goal for many patients with RA, and drug-free remission has been proposed as a potential extended target…Abstract Number: 2216 • ACR Convergence 2022
JAK Inhibitors and Risk of Cancer
Background/Purpose: Recent concerns have been raised about potential increase of cancer risk under JAK inhibitors (JAKi) especially tofacitinib. Discrepant findings have been given by randomized…Abstract Number: PP15 • ACR Convergence 2022
Coordination of Care by a Healthcare Team for Unexpected and Unusual Side Effects Occurring During a Global Pandemic
Background/Purpose: I am a patient who lives with moderate to severe RA. My quality of life is dependent on medications such as a biologic, DMARDs…Abstract Number: 0021 • ACR Convergence 2022
DB-2306, a Novel Anti-TNFα Monoclonal Antibody Drug Conjugate, Is a Promising Novel Therapeutic Approach for Autoimmune Disease
Background/Purpose: Small molecule immune modulators, such as glucocorticoids (GCs), are highly effective in treatment for various inflammatory diseases. However, prolonged systemic administration of GCs is…Abstract Number: 0079 • ACR Convergence 2022
Treatment Persistence in First-Line Biologic and Targeted Synthetic DMARD Users with Dual-Seropositive RA in the Medicare Population
Background/Purpose: The objective of this study was to compare persistence among first-line (1L) abatacept, TNF inhibitors (TNFi), and Janus kinase inhibitors (JAKi) in patients with…Abstract Number: 0198 • ACR Convergence 2022
Patient Perspectives on Janus Kinase Inhibitor Use in the Treatment of Inflammatory Arthritis
Background/Purpose: Janus kinase inhibitors (JAKi) have relatively recently been licensed to treat inflammatory arthritis (IA); specifically rheumatoid arthritis (RA) and psoriatic arthritis (PsA). They differ…Abstract Number: 0250 • ACR Convergence 2022
Performance of Fear Assessment in Inflammatory Rheumatic Diseases (FAIR) Questionnaire in a Cohort of Rheumatoid Arthritis Patients in Argentina
Background/Purpose: RA is a systemic disease that can compromise many aspects of patient health. The increased psychological burden of RA is known and multifactorial, recent…
- « Previous Page
- 1
- …
- 88
- 89
- 90
- 91
- 92
- …
- 188
- Next Page »